Cadila to launch immunosuppressant drug in India

zydusCadila Healthcare, a Ahmedabad headquartered pharmaceutical company owned by Zydus Group, said it has partnered with Switzerland-based global biopharmaceutical company Neovii to launch an drug to reduce the strength of the body’s immune system in India.

The drug named Grafalon is extensively used in solid organ transplants and stem cell transplant, said the company.

The market for transplant-immuno therapies is estimated at Rs 483 crore, the company added.

Zydus will market this therapy through Zydus Trans-immune a division that offers a range of therapies related to transplant medicine.

With the inclusion of Grafalon (R) Zydus Trans-immune becomes a leading player in transplant-immunotherapy segment and will be able to offer the most comprehensive therapy portfolio in solid organ transplant and stem cell transplant.

Organ transplantation is the most preferred option for patients with end-stage organ failure since both survival and quality of life are superior as compared to patients who live without transplantation, the company further added.

One of the major challenges in organ transplantation is graft rejection.

In most cases transplant rejection occurs when transplanted tissue is rejected by the recipient’s immune system which destroys the transplanted tissue.

Likewise, stem cell transplantation remains key treatment option for those suffering from haematological conditions including malignancies.

Transplant outcomes can be improved significantly by the use of immunosuppressant drugs like Grafalon (R).

Grafalon(R) enjoys worldwide recognition among solid organ and stem cell transplant teams and has transformed the way transplant teams manage the care of transplant recipients around the world.

More than 200,000 patients till date, in over 50 countries, have been treated With Grafalon (R) currently an estimated 10000 Solid organ transplant & stem cell transplants are taking place annually across 200 plus transplant centres in India.



Cipla redraws Iran plans with new agreement, to invest Rs 121 cr Cipla said its wholly owned subsidiary of the Company in Netherlands will set up a 75% joint venture with Ahran Tejarat Company for manufacturing and marketing of pharmaceutical products in Iran.An earlier agreement executed by the Company with the Iranian firm has been terminated.The total investment will be euro 16.875 million, which comes to about...
Bliss GVS Healthcare wins three-year contract worth Rs 760 cr from Kenya Bliss GVS Healthcare Ltd said it won a three year contract worth $111.40 mln (Rs 760 cr) from Aon Kenya Insurance Brokers Ltd for provision of medical health care services in Kenya. Bliss GVS Pharma Ltd is a pharmaceutical company based in Mumbai, India.Bliss GVS primarily develops, manufactures and markets products across various therapeuti...
Alembic Pharmaceuticals receives FDA approval for hypertension tablets Alembic Pharmaceuticals Ltd said it received approval from the United States Food & Drug Administration for its abbreviated new drug application for Telmisartan and Amlodipine tablets for hypertension.The Telmisartan and Amlodipine Tablets are equivalent to the Twynsta tablets of Boehringer Ingelheim Pharmaceuticals, Inc.An Abbreviated New Drug ...
Lupin launches injectable iron formulations in India Pharma major Lupin Limited said it launched Iron Isomaltoside injectable iron formulation under two brand names “Isofer” and “Jilazo” in India.Lupin acquired the exclusive rights to market, distribute and sell the injectable formulation from Denmark based Pharmacosmos A/S.The product is currently marketed in 33 countries, including 21 European Union coun...
Dr Reddy’s Labs launches osteoporosis drug in the US Dr Reddy's Laboratories Ltd said it launched raloxifene hydrochloride tablets --used to treat osteoporosis -- in the US market.Raloxifene hydrochloride tablets are a therapeutic equivalent generic version of Evista (raloxifene hydrochloride) tablets. A generic drug is a pharmaceutical drug that is equivalent to a brand-name product in dosage, strength, r...
Uflex launches pouch to extend shelf life for ghee FMCG company Uflex said it launched new pouche for liquids like ghee or clarified butter for long shelf life.The pouch with sonically sealed spout has been offered to Paras Dairy for packing it's ghee.Uflex, founded in 1983, is India’s largest end-to-end flexible packaging company.Jeevaraj Pillai, Joint President, Packaging and New Product Develo...
Nikon launches DSLR D5600 camera Nikon India said it launched a new DSLR camera --Nikon D5600.The DX-format D-SLR is equipped with a vari-angle LCD monitor that flips out and rotates, touch screen operation enhanced with crop function for use use in playback zoom, frame advance bar for users to scroll through images in playback mode easily, time-lapse movie function, etc.The camera ...
Ambrane launches ´BT-5000´ bluetooth speaker @ Rs 1499 IT brand Ambrane India said it launched a new bluetooth speaker BT5000, priced at just Rs 1499.Ambrane is one of the leading IT brands in computer peripherals, Mobile Accessories and No. 1 in Power Banks.The speaker has in-built Magnetic trumpet that improves the quality of perceptible audio output giving the user a loud and crystal clear sound, the...
Aditya Birla´s fashion and retail unit ties up with UK luxury brand Ted Baker Aditya Birla Fashion and Retail Ltd said it entered into agreement with UK based fashion brand Ted Baker.Ted Baker London is a British luxury clothing retail company."We are happy to join hands with Ted Baker and build a strong presence for the brand with Indian consumers. This partnership will enable our consumers to explore to a new world of fashio...
Lypsa Gems to sell via Gitanjali Group’s jewelsouk.com Lypsa Gems and Jewellery Ltd said it tied up with Jewelsouk.com to sell ‘Lypsa Atelier’ branded diamond-studded jewellery.“This tie-up is part of our E-commerce push. Lypsa Atelier is currently available on Flipkart, Snapdeal, Craftsvilla, Shopclues in addition to Jewelsouk.”, said Jeeyan Patwa, Director, Lypsa Gems and Jewellery Ltd.Lypsa plans to s...
OnMobile launches new consumer brand ONMO OnMobile Global Limited launched its new consumer brand, ONMO, and showcased some of its other new products. “The company has been working towards this change for over two years now. It has made significant investments in core technology, product development, processes and people to get ready to serve consumers directly,” said the company.Onmobile ...
Sun Pharma to get dengue vaccine technology from ICGEB Pharma major Sun Pharma said it tied up with research organization International Centre for Genetic Engineering and Biotechnology to develop vaccines for dengue.The vaccine is targeted against all the four serotypes of Dengue virus that cause disease in humans and is being developed to commercialize in Indian and international markets.A serotype is a...
Aarti Industries to return Rs 96 cr to shareholders via buyback Speciality Chemicals company Aarti Industries Ltd said it will buy back12 lakh equity shares at Rs 800 each, aggregating to Rs 96 cr.The company´s Board of Directors approved the equity shares -- representing up to 1.44% of the company's base."The public announcement setting out the process, timelines and other requisite detail will be released in du...
Marksans Pharma gets USFDA approval for synthetic Vitamin D tablets Marksans Pharma Ltd said the United States Food & Drug Administration has given its approval for its paricalcitol capsules -- a synthetic equivalent of Vitamin D.Vitamin D is important for the absorption of Calcium from the stomach and for the functioning of Calcium in the body. Paricalcitol Capsules are therapeutically equivalent to the reference l...
India overdependent on China for medicines – study India may have emerged as a key supplier of generic and affordable medicine for the world market, but it has an "overwhelming dependence" on China for the raw material required to produce these drugs, industry association Assocham said.Indian companies depend on China to supply them with the main raw material in drug making -- known as Active Pharmaceuti...